Capmatinib (Tabrecta) is a targeted therapy medication that plays an important role in the treatment of non-small cell lung cancer associated with specific gene mutations. As a MET kinase inhibitor, it exerts precise effects on MET exon 14 skipping mutations, providing individualized treatment options for patients.

What Are the Indications for Capmatinib (Tabrecta)?

Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC)

Capmatinib is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC).

The patients’ tumors harbor mutations that cause mesenchymal-epithelial transition (MET) exon 14 skipping, as detected by an FDA-approved test.

Patient Selection Criteria

Patients are selected based on the presence of MET exon 14 skipping mutations in tumor or plasma samples.

If MET exon 14 skipping mutations are not detected in plasma samples, tumor tissue testing should be performed if feasible.

Patients must have mutations confirmed by an FDA-approved testing method.

Characteristics of Applicable Populations

Confirmed diagnosis of metastatic non-small cell lung cancer.

Tumors harboring MET exon 14 skipping mutations.

Adult patients (aged ≥ 18 years).

Dosage Form and Characteristics of Capmatinib (Tabrecta)

Dosage Specifications

150 mg tablets: Pale orange-brown, oval, convex film-coated tablets with bevelled edges and no score lines.

200 mg tablets: Yellow, oval, convex film-coated tablets with bevelled edges and no score lines.

Description of 150 mg Tablets

Color: Pale orange-brown.

Shape: Oval, convex film-coated.

Edge Feature: Bevelled edges.

Markings: Imprinted with "DU" on one side and "NVR" on the other side.

Description of 200 mg Tablets

Color: Yellow.

Shape: Oval, convex film-coated.

Edge Feature: Bevelled edges.

Markings: Imprinted with "LO" on one side and "NVR" on the other side.

Storage Methods for Capmatinib (Tabrecta)

Standard Storage Conditions

Storage Temperature: 20°C to 25°C (68°F to 77°F).

Permissible Temperature Excursion Range: 15°C to 30°C (59°F to 86°F).

Important Storage Precautions

Dispense in the original packaging.

Do not remove the desiccant canister from the bottle.

Keep the bottle tightly closed.

Store in a moisture-proof environment.

Shelf Life After First Opening

Use within 6 weeks after the first opening of the bottle.

Discard any unused capmatinib after 6 weeks.